TABLE 2.
Gene | Fold of control | P |
P ≤ 0.05 | ||
AHR | 2.6 | 0.017 |
ARNT | 1.8 | 0.020 |
HIF1A | 1.6 | 0.027 |
JUN | 1.7 | 0.045 |
NFAM12 | 3.0 | <0.001 |
OSM3 | 1.8 | 0.001 |
REL | 1.7 | 0.016 |
P > 0.05 | ||
ARNT2 | 1.0 | 0.97 |
CAMK2G | 1.2 | 0.35 |
CXCL14 | 1.3 | 0.74 |
ERCC1 | 1.3 | 0.11 |
IL2 | 1.1 | 0.61 |
IL6 | 1.3 | 0.14 |
LIF | 1.4 | 0.08 |
NFATC3 | 1.4 | 0.11 |
TNFRSF21 | 1.6 | 0.09 |
Fold of control = 2−∆C′t, where ∆C′t = (Ctgarlic, hour 3 – Ctgarlic, hour 0) – (Ctcontrol, hour 3 – Ctcontrol, hour 0). AHR, aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor nuclear translocator; ARNT2, aryl hydrocarbon receptor nuclear translocator 2; CAMK2G, calcium/calmodulin-dependent protein kinase IIγ Ct, threshold cycle; CXCL14, chemokine (C-X-C motif) ligand 14; ERCC1, excision repair cross-complementation group 1; HIF1A, hypoxia-inducible factor 1α JUN, proto-oncogene c-Jun; LIF, leukemia inhibitory factor; NFAM1, NFAT activating protein with immunoreceptor tyrosine-based activation motif 1; NFATC3, nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 3; OSM, oncostatin M; REL, V-rel avian reticuloendotheliosis viral oncogene homolog; TNFRSF21, tumor necrosis factor receptor superfamily, member 21.
Significant sex × treatment interaction, P = 0.010. Fold-change for women = 5.6 (P < 0.001) and for men = 1.5 (P = 0.32).
Significant sex × treatment interaction, P = 0.007. Fold-change for women = 2.5 (P < 0.001) and for men = 1.2 (P = 0.29).